FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden

hours per response:

0.5

١	Check this box if no longer subject to								
	Section 16. Form 4 or Form 5								
)	obligations may continue. See								
	Instruction 1(b).								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ZUCCONI THEODORE DANIEL					2. Issuer Name and Ticker or Trading Symbol PRO PHARMACEUTICALS INC [PRWP.OB						OB (Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O PRO-PHARMACEUTICALS, INC 7 WELLS AVENUE, SUITE 34				3. Date of Earliest Transaction (Month/Day/Year) 03/26/2009							X Officer (give title Other (specify below) CEO and President					
(Street) NEWTON MA 02459 (City) (State) (Zip)			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				•	Execution Date		Code (Instr.			and 5) Securities Beneficially Owned Follo		Form:	n: Direct I r Indirect I estr. 4) (7. Nature of ndirect Beneficial Dwnership		
								Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)		"	nstr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date Execution Date, if any (Month/Day/Year)		Transaction D Code (Instr. 8) A		Derivative I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	vii(2)		
Stock Option (Right to Buy)	\$0.23	03/24/2009		A		500,000		(1)	03/24/2014	Common Stock	500,000	\$0	500,00	0	D	

Explanation of Responses:

1. The options shall vest as follows provided that Mr. Zucconi is serving as a director of the Company on such date: (i) 50% on March 24, 2010; (ii) 25% on June 24, 2010; (iii) 12.5% on September 24, 2010; (iv) 6.25% on December 24, 2010; and (v) 6.25% on March 24, 2011.

/s/ Maureen E. Foley for Theodore Zucconi

03/26/2009

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.